Prometheus™ - the curative potential of gene therapy for large unmet clinical needs.
While gene therapy has been a subject of extensive research for over 50 years, with more than 62,000 publications on PubMed and 1,000 registered trials on ClinicalTrials.gov, the approvals of the previous decade have been focused on rare diseases. Recent advances in vector design and nucleic acid technologies now allow for the use of gene therapy in a broad range of therapeutic indications, bringing its curative potential to common ailments, at an affordable cost. Remedium has developed Prometheus™ - a revolutionary platform that enables replacement of subcutaneously delivered proteins, as a safe, durable, and pharmacokinetically optimized, single injection gene therapy – for a fraction of the current treatment costs.
62,000+
Research publications
1000+
Clinical trials
1 billion
Doses administered
Gene Manuscript
Goraltchouk A, Lourie J, Hollander JM, Rosen HG, Fujishiro AA, Luppino F, Zou K, Seregin A. Development and Characterization of a First-In-Class Adjustable-Dose Gene Therapy System. Gene. 2024 Apr 23. LINK
Current Gene Therapy Paper
Hollander JM, Goraltchouk A, Liu J, Xu E, Luppino F, McAlindon TE, Zeng L, Seregin A. Single Injection AAV2-FGF18 Gene Therapy Reduces Cartilage Loss and Subchondral Bone Damage in a Mechanically Induced Model of Osteoarthritis. Current Gene Therapy; 2024 Jan 30. LINK
Neuroscience Manuscript
Goraltchouk A, Mankovskaya S, Kuznetsova T, Hladkova Z, Hollander JM, Luppino F, Seregin A. Comparitive Evaluation of rhFGF18 and rhGDF11 Treatment in a Transient Ischemia Stroke Model. Restor Neurol Neurosci; 2024 Feb 15. LINK
Cartilage paper
Hollander JM, Goraltchouk A, Rawal M, Liu J, Luppino F, Zeng L, Seregin A. Adeno-Associated Virus-Delivered Fibroblast Growth Factor 18 Gene Therapy Promotes Cartilage Anabolism. Cartilage. 2023 Mar 6. LINK
ASBMR conference
Goraltchouk A, Hollander JM, Luppino F, Zeng L, Seregin A. Characterization of Novel FGF18 Gene Therapy for the Treatment of Osteoarthritis. Poster session presented at: Annual Meeting of the ASBMR; 2022 Sep 9-12; Austin, TX. LINK
ORS podium presentation
Goraltchouk A, Hollander JM, Luppino F, Zeng L, Seregin A. AAV2-hFGF18 Increases Cartilage Thickness and Promotes Hyaline Cartilage Anabolism. Paper presented at: Orthopaedic Research Society; 2023 Feb 10-14; Dallas, TX. LINK
OARSI podium presentation
Goraltchouk A, Hollander JM, Luppino F, Zeng L, Seregin A. Novel AAV2-FGF18 Chondrogenic Gene Therapy. Osteoarthritis and Cartilage, Volume 31, Supplement 1, S52-S53, March 2023. LINK
vos conference
Goraltchouk A, Hollander JM, Luppino F, Zeng L, Seregin A. Novel AAV2-FGF18 Gene Therapy Promotes Cartilage Anabolism. Paper presented at: Veterinary Orthopedic Society; 2023 Mar 11-18; Big Sky, MT. LINK
AAN conference
Goraltchouk A, Luppino F, Seregin A. Treatment with rhFGF18 Analog Results in Cerebroprotection and Recovery of Motor and Memory Function in a Rat Model of Acute Ischemic Stroke. Poster session presented at: American Academy of Neurology; 2023 Apr 23; Boston, MA. LINK
2023 ASHG Podium
Goraltchouk A, Lourie J, Luppino F, Seregin A, Zou K. Development of a novel lipid nanoparticle-based adjustable gene therapy platform technology. Podium presentation at the American Society of Human Genetics Conference; 2023 Nov 1-5; Washington, DC. LINK
INBC Conference
Goraltchouk A, Mankovskaya S, Kuznetsova T, Hladkova Z, Luppino F, Seregin A. Treatment with rhFGF18 Appears Cerebroprotective in Model of Ischemic Stroke. Podium presentation at the 2023 Neurology and Brain Disorders Conference; 2023 Oct 19-20; Boston, MA. LINK
Neurology and Dementia
Goraltchouk A, Mankovskaya S, Kuznetsova T, Hladkova Z, Luppino F, Seregin A. rhFGF18 and rhGDF11 for the treatment of ischemic stroke. Podium presentation at the 2023 Neurology and Dementia Conference; 2023 Jun 16-17; Rome, Italy. LINK
Remedium Product Pipeline
Learn more
The vector
A vector is the method of delivery for the genetic material, it can be viral, lipid, or polymeric (with or without targeting).
GENE OF INTEREST
The cargo typically contains a gene or genetic sequence of interest, this gene can express a protein that treats the disease.
the cargo
The cargo is the genetic construct delivered by the vector, it can be DNA, RNA, or other nucleic acid derivative.
mechanics
Expression of the therapeutic protein can be regulated by a tissue- or cell-specific promoter and other genetic elements.
Remedium Bio News
Learn moreGet In Touch
We are always interested in starting a new conversation and are looking forward to hearing from you. Thank you in advance for your inquiry and please have a wonderful day!
15 Necco St, Floor 4
Boston, MA
02210
E: info@remedium-bio.com
P: +1 (617) 663 8191